Effect of subcutaneous administration of recombinant human erythropoietin on plasma protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis.
The effect of subcutaneous administration of recombinant human erythropoietin (rHuEPO) on plasma natural coagulation inhibitors (protein C, protein S, and antithrombin III) was evaluated in 10 uremic patients on continuous ambulatory peritoneal dialysis (CAPD). These patients were commenced on a 16 week-course of twice weekly rHuEPO by the subcutaneous route. The hemoglobin increased significantly from 6.9 +/- 1.3 g/dl to 9.6 +/- 1.9 g/dl after subcutaneous rHuEPO treatment (p less than 0.01) at an average dose of 84 +/- 9 U/kg body wt/week. With rHuEPO therapy, a significant increase in platelet counts was observed, albeit within the normal range. A significant increase in the prothrombin time was demonstrated at 6 weeks after treatment and increased activated partial thromboplastin time was observed at 6 weeks and 16 weeks after rHuEPO administration although these measurements still remained in normal range. CAPD patients have comparable or even higher plasma levels of natural coagulation inhibitors compared with healthy controls supporting our previous findings that patients on CAPD have normal plasma levels due to an effective compensatory production despite peritoneal losses of these proteins with CAPD. No change in either the immunological or the functional activity of these natural coagulation inhibitors was demonstrated with rHuEPO therapy and clinical thrombosis was not observed during and after rHuEPO therapy. We conclude that there is no laboratory evidence of increased risk of thrombogenesis due to reduction of natural coagulation inhibitors with rHuEPO therapy.
Lai
K N
KN
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.
Yin
J A
JA
Li
P K
PK
Yuen
P M
PM
Lui
S F
SF
D000279:Administration, Cutaneous; D000990:Antithrombin III / Q000378:metabolism*; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D010446:Peptide Fragments / Q000097:blood*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011486:Protein C / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012259:Ribonuclease, Pancreatic / Q000097:blood*; D014511:Uremia / Q000097:blood* / Q000628:therapy
D010446:Peptide Fragments; D011486:Protein C; D011994:Recombinant Proteins; D004921:Erythropoietin; D000990:Antithrombin III; C074799:ribonuclease A (21-124); D012259:Ribonuclease, Pancreatic